Date: 2012-01-18
Type of information: Production agreement
Compound: production platforms for the biopharmaceutical manufacturing industry
Company: Sartorius Stedim Biotech (Germany) G-Con (USA)
Therapeutic area:
Type agreement: collaboration
manufacturing
production
Action mechanism:
Disease:
Details: Sartorius Stedim Biotech (SSB) and G-Con have agreed to a global collaboration to offer highly advanced and flexible production platforms for the biopharmaceutical manufacturing industry.The new product line will leverage G-Con Manufacturing’s novel modular, mobile clean-room “pods” and Sartorius Stedim Biotech’s broad single-use and reusable product portfolio to create a totally integrated production process platform. SSB has incorporated its products into unit operations for media/buffer preparation, seed fermentation, cell cultivation and harvesting, ultra-diafiltration, membrane chromatography and viral clearance for biopharmaceutical development and manufacturing. Combining SSB’s technology with G-Con’s modular, scalable and flexible pod platform will provide the biopharmaceutical manufacturing industry with an unparalleled set of cost-effective, “plug and play” tools for next-generation manufacturing facilities. Effective immediately, G-Con’s modular containment units are available through SSB’s Integrated Solutions unit and will be rolled out globally in early 2012.
Financial terms:
Latest news:
